Form 8-K - Current report:
SEC Accession No. 0000950170-24-011005
Filing Date
2024-02-05
Accepted
2024-02-05 07:03:22
Documents
14
Period of Report
2024-02-05
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K lxeo-20240205.htm   iXBRL 8-K 40330
2 EX-99.1 lxeo-ex99_1.htm EX-99.1 19731
3 GRAPHIC img46940271_0.jpg GRAPHIC 249092
  Complete submission text file 0000950170-24-011005.txt   525402

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT lxeo-20240205.xsd EX-101.SCH 25988
15 EXTRACTED XBRL INSTANCE DOCUMENT lxeo-20240205_htm.xml XML 4931
Mailing Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010 (212) 547-9879
Lexeo Therapeutics, Inc. (Filer) CIK: 0001907108 (see all company filings)

EIN.: 854012572 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41855 | Film No.: 24593931
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)